Search Results
Mar 18, 2026, 10:01 ET Plant-based Beverage Market to Reach US$71.8 Billion by 2032 Expands Amid Health and Sustainability Trends - Persistence Market Research
Lysine Market by Product Type (L-Lysine Hydrochloride, L-Lysine Sulfate, Others), Form (Powder, Dry Form, Others), Grade, Application, and Regional Analysis for 2026 - 2033
More news about: Persistence Market Research Pvt. Ltd.
Mar 18, 2026, 10:00 ET Swarovski Crystal Business 2025 Results
The company delivered +6% organic growth* vs. the previous year to €1,969m in revenue, supported by +9% like-for-like (L4L) growth*, with L4L increases achieved in 9 out of the top10 markets. Growth was broad-based as all regions and channels grew vs. the previous year, led by North
More news about: Swarovski
Mar 18, 2026, 09:35 ET Telit Cinterion Expands 5G Leadership with New 3GPP Release 18 Modules and FRMCS-Ready Variant
flexibility for custom firmware development and network feature integration.Additional key features include:High-performance L1 + L5 GNSS for precise positioningSupport for up to three Wi-Fi transceivers and two Ethernet interfacesIndustrial temperature range from
More news about: Telit Cinterion
Mar 18, 2026, 09:00 ET PetAg® Launches Dyne™ Soft Chews Nationwide, Bringing Science‑Backed Daily Wellness to Dogs Everywhere
non-sedative support for emotional balance and relaxation, helping dogs stay calm yet alert. Formulated with clinically studied ingredients including L-Tryptophan, L-Theanine Suntheanine®, Valerian Root, KSM-66® Ashwagandha, and Bifidobacterium longum shown to help reduce barking, pacing, and cortisol
More news about: PetAg
Mar 18, 2026, 09:00 ET New Report: Religious Participation Linked to Stronger Academic Outcomes for Students
backgrounds. Authored by Bryant Jensen, Professor of Teacher Education at Brigham Young University and Wheatley Institute Affiliate Scholar, and Irvin L. Scott, Senior Lecturer at Harvard Graduate School of Education and founding director of the Leadership Initiative for Faith and Education (LIFE) at Harvard
More news about: Wheatley Institute
Mar 18, 2026, 09:00 ET LEVI & KORSINSKY, LLP: NUSCALE CEO AND CFO FACE PERSONAL LIABILITY FOR SMR LOSSES
partner. The Court has set April 20, 2026 as the deadline to apply for lead plaintiff appointment.The Named Individual DefendantsJohn L. Hopkins, who has served as NuScale's Chief Executive Officer and Board member since December 2012, and Robert Ramsey Hamady, who has served as Chief
More news about: Levi & Korsinsky, LLP
Mar 18, 2026, 09:00 ET FBRT Investor Alert: FRANKLIN BSP REALTY TRUST, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealed Material Risks: Levi & Korsinsky
ties-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-allegedly-concealed-material-risks-levi--korsinsky-302716798.htmlSOURCE Levi & Korsinsky, LLP
More news about: Levi & Korsinsky, LLP
Mar 18, 2026, 09:00 ET Invesco Expands the Invesco QQQ Innovation Suite with the Launch of Invesco QQQ Equal Weight ETF (QEW)
investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.Invesco Distributors, Inc. 03/26 NA 5299706NOT A DEPOSIT l NOT FDIC INSURED l NOT GUARANTEED BY THE BANK | MAY LOSE VALUE | NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCYContact: Samantha Brandifino,
More news about: Invesco Ltd.
Mar 18, 2026, 08:45 ET DayTraders.com Launches Straight to Live Evaluations, Expanding Its Futures Funding Program for Traders Seeking a Direct Path to Live Capital
operational readiness. Rather than routing traders through a simulated funded stage, S2L is positioned as a streamlined futures funding program for traders who want a clearer path from evaluation to live trading.With S2L, DayTraders.com is targeting active futures traders, industry media and market observers
More news about: DayTraders.com
Mar 18, 2026, 08:25 ET Annals of Family Medicine: EHR-Integrated Social Risk Tool Linked to Improvements in Blood Pressure Control in Primary Care Clinics
Controlled TrialBrenda M. McGrath, PhD; Rachel Gold, PhD, MPH; Jenna Donovan, MPH; Shelby L. Watkins, MPH; Arwen Bunce, MA; Maura Pisciotta, MS; Suzanne Morrissey, PhD; Mary Middendorf, BS; Hannah L. Fein, MS, MPH; Christina R. Sheppler, PhD; Anna C. Edelmann, MScN; Michael C. Leo, PhD; Danielle
More news about: Annals of Family Medicine
Mar 18, 2026, 08:15 ET Hermes Intelligence Names Former Man Group & Balyasny Manager Daniel Sako as CEO
previously worked in alternative data at Man Group and Balyasny Asset Management, where he built data products contributing directly to portfolio manager P&L.
More news about: Hermes Intelligence
Mar 18, 2026, 08:12 ET Dexterity's World Model, Foresight, Unlocks Full Potential on NVIDIA Hardware; Showcased at FedEx Investor Day
picture of the scene from raw multi-modal sensor data. Dexterity's engineering team redesigned the perception pipeline to take full advantage of NVIDIA L4 GPUs and TensorRT, reducing it from 1,508ms to 90ms per cycle, a 17x speedup across three stages: object decomposition, geometric reconstruction, and
More news about: Dexterity AI
Mar 18, 2026, 08:00 ET Sapience Therapeutics to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
physiologic functions, highlighting the β-catenin/BCL9 interaction as a therapeutic target. ST316 was designed to selectively disrupt the β-catenin and BCL9/9L interaction, resulting in disruption of oncogenic Wnt/β-catenin transcriptional activity and potent antitumor activity, with no negative impact on intestinal
More news about: Sapience Therapeutics, Inc.
Mar 18, 2026, 07:49 ET FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis: FRONTIER 1. Presented at WCD 2023, July 3-8.3 Stein Gold, L et al. Icotrokinra Demonstrated Superior Responses Compared with Placebo and Deucravacitinib in the Treatment of Moderate-to-Severe Plaque Psoriasis :
More news about: Johnson & Johnson
Mar 18, 2026, 07:44 ET Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
cancer cell linesSu AY, Purcell C, Zhang S, Zhou L, Uruchurtu AS, El-Deiry WSType: Poster
More news about: Jazz Pharmaceuticals plc
Mar 18, 2026, 07:00 ET Generac Introduces SD1250 & SD1500 Diesel Generators: Smarter Solutions for Mission-Critical Power Applications
generator packaging techniques, with proven durability.The new generators feature:A robust Perkins 5012 V-12, 46L engine delivering maximum durability and power output.A modern common rail fuel system reducing fuel consumption and emissions.Marathon
More news about: Generac Power Systems, Inc.
Mar 18, 2026, 06:00 ET SAFEbuilt Partners with Bermuda on Electronic Plan Review
credentials within a company in the United States."Bermuda has a strong team and a clear commitment to serving the public well," said Victoria L. Cordeiro, MCIP, Director of the Department of Planning. "This partnership gives the Department added support at an important time. It allows us to
More news about: SAFEbuilt
Mar 18, 2026, 06:00 ET Introducing Galileo Mars: Delivering Intelligent Workflows, Now More than 1,100 Companies Licensed
ways to work with Galileo help you get real work done—we've moved from one-shot prompts to intelligent, reusable workflows. In learning, that means L&D teams can blend our research with their own priorities and brand, refine it conversationally, and keep programs current as the business changes. In
More news about: The Josh Bersin Company
Mar 18, 2026, 05:55 ET Dreame Technology expands its product portfolio with the launch of L40 Ultra AE and D20 Ultra All-in-one robotic vacuums in India
innovation.''Dreame L40 Ultra AE19,000Pa Vormax™ Suction with Advanced Brush System: Dreame's proprietary TurboForce motor delivers superior suction power that significantly outperforms industry standards. Dreame L40 Ultra AE comes with the internal rotor
More news about: Dreame Technology
Mar 18, 2026, 04:50 ET Applied Intuition colabora con NVIDIA para acelerar la adopción de la tecnología de conducción autónoma
conducción autónomaLos fabricantes de equipos originales (OEM) ahora disponen de una vía lista para la producción para implementar autonomía L2+ escalable optimizada para plataformas NVIDIA.SUNNYVALE, California, 18
More news about: Applied Intuition, Inc.
Mar 18, 2026, 03:30 ET GoStudent - Crisi dell'istruzione: tra studenti esausti, annoiati e dipendenti dai social media, il 90%[1] mostra sintomi d'ansia
voti, in Italia questa pressione colpisce il 46% degli studenti intervistati, evidenziando un impatto psicofisico rilevante. L'80%[2] dei genitori italiani intervistati ammette che i propri figli mostrano segni di stress legato alla scuola. I sintomi più comuni
More news about: GoStudent
Mar 18, 2026, 01:25 ET Supermicro onthult DCBBS® met nieuwe NVIDIA Vera Rubin NVL72-, HGX Rubin NVL8- en Vera CPU-systemen, ontworpen om de marktintroductietijd van klanten te versnellen
platform dat NVIDIA Vera- en x86-CPU's van de volgende generatie ondersteunt, met een schaal van 72 Rubin GPU's per rack, evenals een DCBBS Liquid-to-Air (L2A) Sidecar CDU-optie voor datacenters zonder vloeistofkoeling.Supermicro's nieuwe NVIDIA Vera CPU-systemen omvatten een 2U-server met ondersteuning
More news about: Super Micro Computer, Inc.
Mar 18, 2026, 00:59 ET Supermicro ने नए NVIDIA Vera Rubin NVL72, HGX Rubin NVL8 और Vera CPU सिस्टम के साथ DCBBS® (Data Center Building Block Solutions) का अनावरण किया, जिसे ग्राहकों के लिए उत्पादों को बाजार में लाने के समय को कम करने के लिए डिज़ाइन किया गया है।
लिक्विड-कूलिंग के बिना डेटा सेंटर्स के लिए DCBBS® Liquid-to-Air (L2A) sidecar CDU विकल्प भी प्रदान करता है।Supermicro के
More news about: Super Micro Computer, Inc.
Mar 17, 2026, 20:30 ET Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs
Details of the Poster Presentation:ATG-125 (B7-H3 x PD-L1 bispecific ADC)Title: ATG-125, a novel B7H3 x PD-L1 bispecific antibody-drug conjugate, demonstrates potent antitumor efficacy by dual targeting of immune evasion and
More news about: Antengene Corporation Limited
Mar 17, 2026, 19:00 ET Verismo Therapeutics to Present Novel Multi-chain KIR-CAR Data - Including Initial Clinical Trial Results for Lead Immuno-Oncology Candidates SynKIR™-110 and SynKIR™-310 - at AACR Annual Meeting 2026
study of KIR-CAR in patients with advanced mesothelin-expressing solid tumorsPresenting Author: Lead Clinical Investigator Janos L. Tanyi, M.D., Ph.D., Perelman School of Medicine at the University of PennsylvaniaSession Title: Clinical Trials Plenary 3: Cellular
More news about: Verismo Therapeutics